Bioassays for TSH Receptor Antibodies: Quo Vadis?

tations of GD [12] . TSHR bioassays show outstanding features. The biological activity of specific immunoglobulins is directly assessed on a fully functional TSHR holoreceptor expressed on intact live cells, a platform that is easily adaptable and tailored to detect Ab of specific function. The TSHR protein structure can be bioengineered and stably expressed in cell lines with protocols optimized for detection of TSAb or blocking Ab (TBAb). Another feature is the autoreactivity of an individual patient is revealed with added clinical value; the bioassay of TSHRAb measures the Ab function that is highly correlated with GD activity [13] . Furthermore, monitoring of TSAb levels and TSAb titers adds another dimension to the assessment of GD activity with potential to predict relapse or remission of individual patient [14] . High persistent TSAb levels are associated with active and severe systemic manifestations with poor responses to therapy [15] . In contrast, low TSAb levels are associated with patients in remission. Thus, bioassays may improve the personalized management of GD patients. In this issue of European Thyroid Journal , a new bioassay is introduced which uses a frozen Chinese hamster ovary cell line expressing the TSHR, cAMP-gated calcium channel and aequorin [16] . The principle of the method is that the TSHR-induced increase in intracellular cAMP leads to the direct activation of the cyclic nucleotide-gated calcium channel, the resulting intracellular calcium influx then activating an intracellular photoprotein, aequorin, which emits a blue light at relaxation, the intensity of which is therefore correlated with the degree of TSHR activation. Activated Gs-coupled adenylate cyclase inAutoantibodies (Ab) to the TSH receptor (TSHR) are responsible for many of the clinical manifestations of Graves’ disease (GD) and are specific biomarkers of this autoimmune thyroid disorder (AITD) [1–3] . These Ab can be measured either via competitive-binding immunoassays or with bioassays [4] . Antibody-binding assays only report the presence or absence of TSHR-Ab and their concentrations, but do not indicate their functional activity. Bioassays, in contrast, indicate whether TSHRAb have stimulatory or blocking activity [5] . Historically, bioassays for TSHR-Ab were research tools used to study the pathophysiology of GD. Recently, however, there are increasing data that demonstrate the clinical utility of TSHR-Ab bioassays in the diagnosis and management of patients with GD and in the characterization of AITD patients with hyperthyroidism and hypothyroidism [6] . Advances in protein and cellular bioengineering have facilitated the development of improved bioassays for measuring the biological activity of molecules and this has been specifically and successfully applied to TSHRAb [7] . TSHR bioassays are functional cell-based tests that directly assess the bioactive immunoglobulins having either stimulating or inhibitory input on the TSHR cAMP-dependent signaling [8] . TSHR-stimulating Ab (TSAb) evoke metabolic changes and/or cytokine responses within TSHR-expressing target cells [9] . Bioassays for TSHR-Ab measure the ability of these Ab to either stimulate or block TSHR signal transduction [10] . These functional activities of TSHR-Ab highly correlate with activity of the thyroid in patients with GD [11] . In addition, they are associated with extrathyroidal manifesPublished online: February 28, 2015